Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine eluted cardiovascular frame and its preparing process

A cardiovascular and drug technology, applied in the field of balloon-expandable stents, can solve problems such as unfavorable popularization and use, and achieve the effects of overcoming intolerance to body fluid washout, preventing late thrombosis, and promoting healing

Inactive Publication Date: 2002-06-26
EAST CHINA UNIV OF SCI & TECH +1
View PDF4 Cites 48 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The technical problem to be solved in the present invention is to disclose a drug-eluting cardiovascular stent and a preparation method thereof. A layer of biodegradable polymer grafted heparin with anti-restenosis function is coated on the stent. Soon after the injection, a large amount of anti-restenotic drugs are released to fully inhibit the intimal hyperplasia. The sustained and stable release of heparin can prevent the occurrence of acute and subacute thrombosis, and at the same time can promote the healing of the damaged vessel wall and prevent the occurrence of late thrombosis. The subacute thrombus and long-term restenosis existing in the prior art and the preparation technology are relatively complicated, and harmful substances (ethyleneimine) are introduced, which is not conducive to popularization and use, and meets people's needs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine eluted cardiovascular frame and its preparing process
  • Medicine eluted cardiovascular frame and its preparing process

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Preparation of embodiment 1 biodegradable material:

[0025] Weigh 70 parts of L-LA, 5 parts of GA and 25 parts of ε-CL in a dry polymerization bottle with a stirring bar, and use N 2 Replaced 3 times, placed in an oil bath at 160°C, after melting, added a certain volume of 0.02g / ml stannous octoate chloroform solution (catalyst amount is 0.02wt% of monomer mass), removed chloroform under reduced pressure, and reacted under stirring After 5h, the polymer was dissolved with chloroform and precipitated with ethanol. The molecular weight of the obtained polymer was characterized by gel permeation chromatography (GPC), and the molecular weight was greater than 100,000.

Embodiment 2

[0026] Example 2 Preparation of heparinized poly(lactic acid-glycolic acid-amino acid):

[0027] Weigh 0.1mol L-lactide and 0.05mol morpholine dione derivative monomer containing benzyloxy-protected glutamic acid in a dry polymerization bottle with a stirring bar, and use N 2 Replace 3 times, place in 160°C oil bath, after melting, add a certain volume of 0.02g / ml stannous octoate chloroform solution, remove chloroform under reduced pressure, react for 5h under stirring, dissolve polymer with chloroform, and precipitate with ethanol. The obtained polymer is de-benzyloxyl grouped with Pd / C catalyst and hydrogen gas bubbling for 40 to obtain poly(lactic acid-glycolic acid-glutamic acid).

[0028] Heparin contains amino groups and carboxyl groups. Poly(lactic acid-glycolic acid-aspartic acid) is dissolved in a mixed solvent of tetrahydrofuran and water, and a certain amount is weighed (according to the Gel Permeation Chromatography of the polymer, refer...

Embodiment 3

[0030] Dissolve 0.1 gram of heparinized poly(lactic acid-glycolic acid-amino acid) and 0.1 gram of anti-restenosis drug rapamycin (Rampamycin) in 5 ml of chloroform, and then figure 1 The balloon-expandable stent shown is soaked in the solution for about 30 seconds, taken out and blown dry for later use. The stent can overcome restenosis in the stent and prevent the formation of acute and subacute thrombus. Meanwhile, the heparin has an anti-inflammation effect, can inhibit the foreign body inflammatory reaction of the stent, and promote the healing of the wound on the inner wall of the blood vessel.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A medicine eluted cardiovascular frame is composed of expandible support and the medicine coated biodegradable layer coated on the said frame. The said biodegradable material contains one of the homopolymer and copolymer of glycollide, L-lactide or epsilon-caprolactone, and the copolymer of multi-group amino acids. The medicine can resist the cardiovascular narrowness. The process for preparing the said support includes such steps as preparing the said expandible support, immersing it in the mixture of the said medicine, biodegradable material and solvent, and drying. It can prevent thrombosis.

Description

technical field [0001] The invention relates to a medical stent, in particular to a balloon-expandable stent capable of releasing therapeutic drugs for cardiovascular. Background technique [0002] In 1964, Dotter and Judkings (Dotter CT, Jukines MP. Tranaluminal treatmant of arteriosclerotic obstruction, 1964, 30: 654) proposed the concept of percutaneous transluminal angioplasty, and assumed that silicone rubber or plastic was used to support the blood vessel to maintain the lumen of the blood vessel. In 1987, Sigwart (Sigwart U, et al. Intravascular stents to prevent occlusion and restenosis after tranaluminal angioplasty. NEngl JMed, 1987; 316: 701) and others used intravascular metal stents for coronary arteries for the first time. Obstructive disease offers a great way to go. [0003] An ideal stent should have the following characteristics: (1) better biocompatibility: minimal procoagulant effect, less likely to cause blood coagulation reaction and thrombus after imp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61F2/90A61L31/10
Inventor 程树军唐智荣饶炬曾敏
Owner EAST CHINA UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com